Dbv Technologies S.A. (DBVT) — SEC Filings
Dbv Technologies S.A. (DBVT) — 4 SEC filings. Latest: ARS (May 11, 2026). Includes 2 8-K, 1 ARS, 1 10-K.
View Dbv Technologies S.A. on SEC EDGAR
Overview
Dbv Technologies S.A. (DBVT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: DBV Technologies S.A. filed an 8-K on March 26, 2026, reporting results of operations and financial condition. The filing includes financial statements and exhibits, with specific details to be found within the provided documents.
Sentiment Summary
Across 4 filings, the sentiment breakdown is: 3 neutral, 1 mixed. The dominant filing sentiment for Dbv Technologies S.A. is neutral.
Filing Type Overview
Dbv Technologies S.A. (DBVT) has filed 1 ARS, 2 8-K, 1 10-K with the SEC between Mar 2026 to May 2026.
Recent SEC Filings (4)
| Date | Form | Description | Risk |
|---|---|---|---|
| May 11, 2026 | ARS | ARS Filing | |
| Apr 30, 2026 | 8-K | 8-K Filing | |
| Mar 26, 2026 | 8-K | DBV Technologies Files 8-K for Financial Results | low |
| Mar 26, 2026 | 10-K | DBV Technologies Eyes 2026 FDA Filings for Peanut Allergy Patch | high |
Risk Profile
Risk Assessment: Of DBVT's 2 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 1 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Langerhans cells
Industry Context
The biopharmaceutical industry, particularly in the allergy and immunology space, is characterized by significant R&D investment and a high degree of regulatory scrutiny. Companies are focused on developing novel therapies for unmet medical needs, with a growing emphasis on personalized medicine and less invasive treatment modalities. The competitive landscape includes both established pharmaceutical giants and emerging biotech firms, all vying for market share through innovation and clinical differentiation.
Top Tags
financial-results (1) · 8-k (1) · operations (1) · Biotechnology (1) · Food Allergy (1) · Immunotherapy (1) · Clinical Trials (1) · FDA Approval (1) · Peanut Allergy (1) · Pharmaceuticals (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of voting and non-voting common equity held by non-affiliates | $250.9 million | as of June 30, 2025, indicating current market valuation |
| Ordinary shares outstanding | 296,042,447 | as of March 25, 2026 |
| Target age group for Viaskin Peanut Patch BLA submission | 1-3 years old | planned for second half of 2026 |
| Estimated children ages 1-7 in the U.S. with peanut allergy | 670,000 | represents the potential market size for Viaskin Peanut Patch |
| Estimated allergists in the U.S. | 4,500 | target for DBVT's specialty sales force |
| Size of anticipated specialty sales force | 50-70 | to engage 90% of U.S. allergists |
| Estimated children in the United States allergic to peanuts | 1.6 million | based on a 2018 publication, reflecting increasing prevalence |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Dbv Technologies S.A. (DBVT)?
Dbv Technologies S.A. has 4 recent SEC filings from Mar 2026 to May 2026, including 2 8-K, 1 ARS, 1 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DBVT filings?
Across 4 filings, the sentiment breakdown is: 3 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Dbv Technologies S.A. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Dbv Technologies S.A. (DBVT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Dbv Technologies S.A.?
Key financial highlights from Dbv Technologies S.A.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DBVT?
The investment thesis for DBVT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Dbv Technologies S.A.?
Key executives identified across Dbv Technologies S.A.'s filings include Langerhans cells.
What are the main risk factors for Dbv Technologies S.A. stock?
Of DBVT's 2 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Dbv Technologies S.A.?
Forward guidance and predictions for Dbv Technologies S.A. are extracted from SEC filings as they are enriched.